The effectivity of glibenclamide treatment seems convincing given the facts that: (1) the drug much more potently inhibits SUR1-TRPM4 channels than TRPM4 channels [275]; (2) SUR1-TRPM4 channels are upregulated only in injured CNS tissues [220,249]; (3) glibenclamide treatment has a long therapeutic window [239]; and (4) glibenclamide treatment is free of major side effects (there is a small risk of hypoglycemia, which can be well managed or greatly reduced by intravenous application) [209]. The gene discussed is TRPM4; the disease is Hypoglycemia.